Anavex Life Sciences Corp (AVXL)

[falconer66a]

Hypertension Relief — A New, Gigantic Anavex Factor

Whoa! Ponder, if you will, the implications of Anavex 2-73 as a safe, effective new anti-hypertensive drug, able to reduce chronic high blood pressure to safer, non-pathogenic levels.

One reliable source, the Centers for Disease Control (https://www.cdc.gov/bloodpressure/faqs.htm) states that about 75 million Americans have high blood pressure. Look it up. Discover, if you don’t yet know, the profound implications of chronic hypertension. High blood pressure is one condition every practitioner would love to effectively treat. The outcomes of normalized, induced blood pressure are profound.

As with the central nervous system diseases Anavex is presently targeting, Alzheimer’s, Parkinson’s, multiple sclerosis, et al., hypertension requires billions upon billions in health care costs, public, private, and institutional.

I and others have laid out, to a degree, the profound health care cost implications of Anavex 2-73 in the treatment and prevention (prophylaxis) of the targeted CNS diseases. That will be transformative for 21st-century medicine.

Likewise, the cost impacts of Anavex 2-73 as a safe, effective soporific, treating and correcting insomnia have been laid out previously.

Now, it’s Anavex effective against hypertension, high blood pressure. Should Anavex 2-73 provide global, universal treatment of hypertension, as this peer-reviewed journal article suggests, the financial outcomes are probably greater than all of the other Anavex applications combined.

As with every other segment of the Anavex story, it’s too good to be true — until the unique mechanisms of action (plural) for the Anavex sigma-1 receptor agonists are understood and recognized. In summary, they force the cell to function normally, properly. And when cells function properly, organ systems can function normally too. In this case, it’s the cardiovascular system, with normalized or non-pathogenic blood pressures.

Sure wish I could buy some more AVXLs. But I’m fully positioned.

[This author advises that his postings should not be used to prompt any AVXL buy or sell decision. Anavex Life Sciences Corp is presently a small, no-revenues, no-product start up pharmaceutical. It may have a great future, as its science is unique and effective. But, of course, never put at risk any non-discretionary funds.]